Financial Times corporate logo 2026.svg

11 November 2026

Should we be testing more drugs on newborn babies? As reckless as this may sound, not carrying out clinical trials involving very young infants could be putting them at greater risk. The fact that they are such a vulnerable population is one reason why newborns are usually excluded from pivotal clinical trials. Yet, paradoxically, it is their vulnerability that makes them among those most in need of the protection that drugs can provide. Without it, doctors are less able to treat them properly.